Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Ultrasound Med Biol. 2022 Nov 26;49(2):616–625. doi: 10.1016/j.ultrasmedbio.2022.10.020

Table 3:

Study results on nodal burden

Subjects nodal burden
 • Total subjects studied n= 79
 • Positive for metastatic disease n= 18 (22.8%)
 • Negative for metastatic disease n= 61 (77.2%)
Lymph node nodal burden
 • Total sentinel lymph nodes surgically excised n= 252
 • Positive for metastatic disease n= 34 (13.5%)
 • Negative for metastatic disease n= 218 (86.5%)
Lymphosonography nodal burden
 • Total sentinel lymph nodes n= 217
 • Positive for metastatic disease n= 34 (15.7%)
 • Negative for metastatic disease n= 183 (84.3%)
Blue dye nodal burden
 • Total sentinel lymph nodes n= 158
 • Positive for metastatic disease n= 18 (11.4%)
 • Negative for metastatic disease n= 140 (88.6%)
Radioactive tracer nodal burden
 • Total sentinel lymph nodes n= 222
 • Positive for metastatic disease n= 23 (10.4%)
 • Negative for metastatic disease n= 199 (89.6%)
Ex vivo UCA nodal burden
 • Total sentinel lymph nodes n= 223
 • Positive for metastatic disease n= 34 (15.2%)
 • Negative for metastatic disease n= 189 (84.8%)
Sentinel lymph nodes positive for metastatic disease
 • Total sentinel lymph nodes n= 34
 • Lymphosonography n= 34 (100%)
 • Blue dye n= 18 (52.9%)
 • Radioactive tracer n= 23 (67.6%)
 • Ex vivo UCA n= 34 (100%)